Vancomycin and daptomycin minimum inhibitory concentration distribution and occurrence of heteroresistance among methicillin-resistant Staphylococcus aureus blood isolates in Turkey

BMC Infectious Diseases

Volumn 13, Issue 1, 2013, Pages

  Sancak, Banu ^a   Yagci, Server ^b   Gür, Deniz ^a   Gülay, Zeynep ^c   Ogunc, Dilara ^d   Söyletir, Güner ^e   Yalcin, Ata N ^d   Dündar, Devrim T ^f   Topçu, Ayşe W ^f   Aksit, Filiz ^g   Usluer, Gaye ^g   Özakin, Cüneyt ^h   Akalin, Halis ^h   Hayran, Mutlu ^a   Korten, Volkan ^e  

^a HACETTEPE UNIVERSITY   (Turkey)

^b Kecioren Research and Training Hospital   (Turkey)

^c DOKUZ EYLUL UNIVERSITY   (Turkey)

^d AKDENIZ UNIVERSITY   (Turkey)

^e MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^f KOCAELI UNIVERSITY   (Turkey)

^g GAZI UNIVERSITY   (Turkey)

^h ULUDAG UNIVERSITY   (Turkey)

Author keywords

Blood isolates; Daptomycin; Heteroresistance; MIC; MRSA; Vancomycin

Indexed keywords

DAPTOMYCIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BLOOD SAMPLING; BROTH DILUTION; CONTROLLED STUDY; EPSILOMETER TEST; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; SENSITIVITY AND SPECIFICITY; TURKEY (REPUBLIC); UNIVERSITY HOSPITAL; VANCOMYCIN INTERMEDIATE STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BACTEREMIA; DAPTOMYCIN; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; PREVALENCE; STAPHYLOCOCCAL INFECTIONS; TURKEY; VANCOMYCIN; VANCOMYCIN RESISTANCE;

EID: 84889859403     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-13-583     Document Type: Article

References (30)

1. Hsu DI, Hidayat LK, Quist R, Hindler J, Karlsson A, Yusof A, Wong-Beringer A. Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of meticillin-resistant Staphylococcus aureus (MRSA) infections. Int J Antimicrob Agents 2008, 32(5):378-385. 10.1016/j.ijantimicag.2008.05.007, 18701261.
2. Lodise TP, Graves J, Evans A, Graffunder E, Helmecke M, Lomaestro BM, Stellrecht K. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 2008, 52(9):3315-3320. 10.1128/AAC.00113-08, 2533486, 18591266.
3. Adam HJ, Louie L, Watt C, Gravel D, Bryce E, Loeb M, Matlow A, McGeer A, Mulvey MR, Simor AE, et al. Detection and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates in Canada: results from the Canadian Nosocomial Infection Surveillance Program, 1995-2006. Antimicrob Agents Chemother 2010, 54(2):945-949. 10.1128/AAC.01316-09, 2812162, 19949062.
4. Musta AC, Riederer K, Shemes S, Chase P, Jose J, Johnson LB, Khatib R. Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years. J Clin Microbiol 2009, 47(6):1640-1644. 10.1128/JCM.02135-08, 2691078, 19369444.
5. Park KH, Kim ES, Kim HS, Park SJ, Bang KM, Park HJ, Park SY, Moon SM, Chong YP, Kim SH, et al. Comparison of the clinical features, bacterial genotypes and outcomes of patients with bacteraemia due to heteroresistant vancomycin-intermediate Staphylococcus aureus and vancomycin-susceptible S. aureus. J Antimicrob Chemother 2012, 67(8):1843-1849. 10.1093/jac/dks131, 22535621.
6. Rybak MJ, Leonard SN, Rossi KL, Cheung CM, Sader HS, Jones RN. Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007). J Clin Microbiol 2008, 46(9):2950-2954. 10.1128/JCM.00582-08, 2546725, 18632899.
7. Van Hal SJ, Wehrhahn MC, Barbagiannakos T, Mercer J, Chen D, Paterson DL, Gosbell IB. Performance of various testing methodologies for detection of heteroresistant vancomycin-intermediate Staphylococcus aureus in bloodstream isolates. J Clin Microbiol 2011, 49(4):1489-1494. 10.1128/JCM.02302-10, 3122872, 21270232.
8. Clinical and Laboratory Standards Institute Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically-Eighth Edition: Approved Standard M07-A8 2009, PA, USA: CLSI, Wayne, Clinical and Laboratory Standards Institute.
9. Carroll KC, Glanz BD, Borek AP, Burger C, Bhally HS, Henciak S, Flayhart D. Evaluation of the BD Phoenix automated microbiology system for identification and antimicrobial susceptibility testing of Enterobacteriaceae. J Clin Microbiol 2006, 44(10):3506-3509. 10.1128/JCM.00994-06, 1594749, 17021074.
10. Wootton M, Howe RA, Hillman R, Walsh TR, Bennett PM, MacGowan AP. A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. J Antimicrob Chemother 2001, 47(4):399-403. 10.1093/jac/47.4.399, 11266410.
11. Wootton M, MacGowan AP, Walsh TR, Howe RA. A multicenter study evaluating the current strategies for isolating Staphylococcus aureus strains with reduced susceptibility to glycopeptides. J Clin Microbiol 2007, 45(2):329-332. 10.1128/JCM.01508-06, 1829006, 17108069.
12. Edwards B, Milne K, Lawes T, Cook I, Robb A, Gould IM. Is vancomycin MIC "creep" method dependent? Analysis of methicillin-resistant Staphylococcus aureus susceptibility trends in blood isolates from North East Scotland from 2006 to 2010. J Clin Microbiol 2012, 50(2):318-325. 10.1128/JCM.05520-11, 3264194, 22135252.
13. Kehrmann J, Kaase M, Szabados F, Gatermann SG, Buer J, Rath PM, Steinmann J. Vancomycin MIC creep in MRSA blood culture isolates from Germany: a regional problem?. Eur J Clin Microbiol Infect Dis 2011, 30(5):677-683. 10.1007/s10096-010-1140-7, 21229280.
14. Steinkraus G, White R, Friedrich L. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. J Antimicrob Chemother 2007, 60(4):788-794. 10.1093/jac/dkm258, 17623693.
15. Reynolds R, Hope R, Warner M, Macgowan AP, Livermore DM. Ellington MJ, on behalf of the BEWPoRS: Lack of upward creep of glycopeptide MICs for methicillin-resistant Staphylococcus aureus (MRSA) isolated in the UK and Ireland 2001-07. J Antimicrob Chemother 2012, 67(12):2912-2918. 10.1093/jac/dks324, 22899805.
16. Sader HS, Fey PD, Limaye AP, Madinger N, Pankey G, Rahal J, Rybak MJ, Snydman DR, Steed LL, Waites K. Evaluation of vancomycin and daptomycin potency trends (MIC creep) against methicillin-resistant Staphylococcus aureus isolates collected in nine U.S. medical centers from 2002 to 2006. Antimicrob Agents Chemother 2009, 53(10):4127-4132. 10.1128/AAC.00616-09, 2764224, 19635961.
17. Soriano A, Marco F, Martinez JA, Pisos E, Almela M, Dimova VP, Alamo D, Ortega M, Lopez J, Mensa J. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008, 46(2):193-200. 10.1086/524667, 18171250.
18. Khatib R, Jose J, Musta A, Sharma M, Fakih MG, Johnson LB, Riederer K, Shemes S. Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother 2011, 66(7):1594-1599. 10.1093/jac/dkr169, 21525024.
19. Van Hal SJ, Lodise TP, Paterson DL. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis 2012, 54(6):755-771. 10.1093/cid/cir935, 22302374.
20. Howden BP, Davies JK, Johnson PD, Stinear TP, Grayson ML. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev 2010, 23(1):99-139. 10.1128/CMR.00042-09, 2806658, 20065327.
21. Prakash V, Lewis JS, Jorgensen JH. Vancomycin MICs for methicillin-resistant Staphylococcus aureus isolates differ based upon the susceptibility test method used. Antimicrob Agents Chemother 2008, 52(12):4528. 10.1128/AAC.00904-08, 2592869, 18838599.
22. Sader HS, Rhomberg PR, Jones RN. Nine-hospital study comparing broth microdilution and Etest method results for vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2009, 53(7):3162-3165. 10.1128/AAC.00093-09, 2704704, 19398641.
23. Satola SW, Farley MM, Anderson KF, Patel JB. Comparison of detection methods for heteroresistant vancomycin-intermediate Staphylococcus aureus, with the population analysis profile method as the reference method. J Clin Microbiol 2011, 49(1):177-183. 10.1128/JCM.01128-10, 3020420, 21048008.
24. Walsh TR, Bolmstrom A, Qwarnstrom A, Ho P, Wootton M, Howe RA, MacGowan AP, Diekema D. Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides. J Clin Microbiol 2001, 39(7):2439-2444. 10.1128/JCM.39.7.2439-2444.2001, 88167, 11427551.
25. Sancak B, Ercis S, Menemenlioglu D, Colakoglu S, Hascelik G. Methicillin-resistant Staphylococcus aureus heterogeneously resistant to vancomycin in a Turkish university hospital. J Antimicrob Chemother 2005, 56(3):519-523. 10.1093/jac/dki272, 16046461.
26. Lin SY, Chen TC, Chen FJ, Chen YH, Lin YI, Kristopher Siu L, Lu PL. Molecular epidemiology and clinical characteristics of hetero-resistant vancomycin intermediate Staphylococcus aureus bacteremia in a Taiwan Medical Center. J Microbiol Immunol Infect 2012, 45(6):435-441. 10.1016/j.jmii.2012.05.004, 22749725.
27. Van Hal SJ, Paterson DL. Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates. Antimicrob Agents Chemother 2011, 55(1):405-410. 10.1128/AAC.01133-10, 3019654, 21078939.
28. Maor Y, Rahav G, Belausov N, Ben-David D, Smollan G, Keller N. Prevalence and characteristics of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia in a tertiary care center. J Clin Microbiol 2007, 45(5):1511-1514. 10.1128/JCM.01262-06, 1865872, 17344363.
29. Kirby A, Graham R, Williams NJ, Wootton M, Broughton CM, Alanazi M, Anson J, Neal TJ, Parry CM. Staphylococcus aureus with reduced glycopeptide susceptibility in Liverpool, UK. J Antimicrob Chemother 2010, 65(4):721-724. 10.1093/jac/dkq009, 20124288.
30. Kelley PG, Gao W, Ward PB, Howden BP. Daptomycin non-susceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): implications for therapy after vancomycin treatment failure. J Antimicrob Chemother 2011, 66(5):1057-1060. 10.1093/jac/dkr066, 21393156.